Roche first-half 2024 sales grow 5%

25 July 2024

Shares of Swiss pharma giant Roche (ROG: SIX) edged up 2.4% in morning trading after the Swiss pharma giant posted a strong set of first-half 2024 financials.

Group sales were up by 5% at constant exchange rates (stable in Swiss francs) at 29.8 billion francs ($33.5 billion). While the appreciation of the Swiss franc slowed against most currencies, it had an adverse impact on the results presented in Swiss francs compared to constant exchange rates, the company noted.

First-half adjusted operating profit increased 4% to 11.3 billion francs ($12.8 billion), beating analysts' consensus estimate of 10.5 billion francs, based on LSEG data.Core operating profit grew by 11% (4% in francs), driven by higher sales and cost management, and beating analysts’ estimates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK